pharma · 2019-nCoV
Jieming QU
Jieming QU is a pharma organization headquartered in CN. Primary therapeutic focus areas include 2019-nCoV. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 1
- Patents
- 0
Arbidol
Approved · small molecule · 2019-nCoV
Arbidol for 2019-nCoV is a Approved program (small_molecule) at Jieming QU with 1 ClinicalTrials.gov record(s).
Internal code Abdrcspc202001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Jieming QU
- Phase
- Approved
- Modality
- small_molecule
- Indication
- 2019-nCoV
- Status
- completed
- Trials
- 1